Yanfeng Zhang

This inventor holds 59 USPTO granted patents and 12 published patent applications, plus 13 CIPO patents and 22 EPO patents, primarily in Crystalline Forms (CPC class C07D). Top assignees: Crystal Pharmatech Co., Ltd., Crystal Pharmaceutical (Suzhou) Co., Ltd., Merck Sharp + Dohme Corp.. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yanfeng Zhang. Retrieved from https://idiyas.com/inventor/yanfeng-zhang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 59 (Patent Applications = 12)

% Patents Active = 52.5

CIPO Patents = 13 (Patent Applications = 35)

EPO Patents = 22 (Patent Applications = 41)

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 72(Granted Patents)

Forward Citations (Not Self Cited) = 58(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Panan, CN (2014 - 2015)
Zhejiang, CN (2014 - 2016)
Jiangsu, CN (2018 - 2023)
Suzhou, CN (2017 - 2024)

Company Filing History:

22 out of 22

Crystal Pharmatech Co., Ltd.

patents

15 out of 20

Crystal Pharmaceutical (Suzhou) Co., Ltd.

patents

8 out of 2,405

Merck Sharp + Dohme Corp.

Suzhou Pengxu Pharmatech Co., Ltd.

patents

6. 3 out of 99

Agios Pharmaceuticals, Inc.

patents

7. 2 out of 70

Anacor Pharmaceuticals, Inc.

patents

8. 2 out of 95

Glaxosmithkline Intellectual Property (No.2) Limited

patents

9. 1 out of 1

Crystal Pharmaceuticals (Suzhou) Co., Ltd.

patent

10. 1 out of 2

Crystal Pharmatech Inc.

patents

11. 1 out of 3

Napp Pharmaceutical Group Limited

patents

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

Areas of Expertise:

Crystalline Forms

Antifungal Agents

JAK Inhibitors

Receptor Modulators

Preparation Methods

Pharmaceutical Use

Therapeutically Active Compounds

Viral-Protein Inhibitors

Androgen Receptor Antagonists

Sodium-Glucose Co-Transporter

Crystalline Compounds

Selective S1P1 Modulators

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12060439 - Polymorph of echinocandin antifungal agent (2024-08-13),

2. 11897848 - Crystalline forms of ozanimod and processes for preparation thereof (2024-02-13),

3. 11773113 - Crystal forms of crisaborole in free form and preparation method and use thereof (2023-10-03),

4. 11680050 - Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof (2023-06-20),

5. 11649217 - Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof (2023-05-16),

6. 11447506 - Crystal forms of crisaborole in free form and preparation method and use thereof (2022-09-20),

7. 11339158 - Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof (2022-05-24),

8. 11149004 - Crystalline form of EB-1020, processes for preparation and use thereof (2021-10-19),

9. 11136347 - Crystalline forms of a fatty acid bile acid conjugate, preparation method thereof and use thereof (2021-10-05),

10. 11124517 - Crystal form of Baricitinib and preparation method thereof (2021-09-21),

11. 11117876 - Crystalline form of ozanimod hydrochloride, and processes for preparation thereof (2021-09-14),

12. 11117871 - Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof (2021-09-14),

13. 11111223 - Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof (2021-09-07),

14. 11091494 - Crystal form of acalabrutinib and preparation method and use thereof (2021-08-17),

15. 11066384 - Crystalline forms of ARN-509, preparation method and use thereof (2021-07-20),

Title: Yanfeng Zhang: A Pioneer in Antifungal and Autoimmune Disease Research

Introduction

Yanfeng Zhang, a prominent inventor based in Suzhou, China, has made significant contributions to the field of pharmaceuticals through his innovative research. With a remarkable portfolio of 59 patents, Zhang is recognized for his pioneering work in developing new drug formulations that address critical healthcare challenges.

Latest Patents

Among his latest innovations, Zhang has introduced two noteworthy patents. The first is a polymorph of an echinocandin antifungal agent, focusing on crystalline polymorphs and novel methods for their preparation. This invention enhances the efficacy of antifungal treatments through improved drug stability and bioavailability.

The second significant contribution involves novel crystalline forms of ozanimod, designated as CS9, CS10, and CS11. These crystalline forms are specifically designed for treating autoimmune diseases such as multiple sclerosis and ulcerative colitis. The innovative preparation methods for these forms provide advantages in solubility, stability, hygroscopicity, and processability, making them invaluable for drug development.

Career Highlights

Throughout his career, Yanfeng Zhang has contributed to the pharmaceutical industry through his work at companies such as Crystal Pharmatech Co., Ltd. and Crystal Pharmaceutical (Suzhou) Co., Ltd. His extensive research and development efforts have positioned him as a leader in the pursuit of effective treatment options for complex medical conditions.

Collaborations

Zhang has also collaborated with notable colleagues in his field, including Minhua Chen and Xiaoyu Zhang. These partnerships have fostered a collaborative environment that promotes innovative thinking and accelerates the development of groundbreaking pharmaceutical solutions.

Conclusion

In summary, Yanfeng Zhang's impressive track record of 59 patents showcases his dedication to improving healthcare through innovation. His latest advancements in antifungal and autoimmune disease medications highlight the importance of continued research and development in the pharmaceutical industry. Zhang’s work not only contributes to scientific knowledge but also provides hope for patients battling various health issues.

Profile summary based on public USPTO records.